We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Janssen has submitted a marketing authorisation extension application to the European Medicines Agency (EMA) for paliperidone palmitate six-monthly (PP6M) as a maintenance treatment for adults living with schizophrenia.